134 related articles for article (PubMed ID: 37345408)
1. Perfluoro-tert-butyl Group-Derived Capmatinib: Synthesis, Biological Evaluation and Its Application in
Zhang X; Wang L; Huang R; Wang J; Yan Q
Chembiochem; 2023 Oct; 24(19):e202300354. PubMed ID: 37345408
[TBL] [Abstract][Full Text] [Related]
2. High-Contrast and Fast-Removable
Gervits LL; Sigan AL; Markova AA; Gulyaev MV; Pavlova OS; Ozhiganov RM; Pirogov YA
ChemMedChem; 2023 Sep; 18(18):e202300239. PubMed ID: 37387552
[No Abstract] [Full Text] [Related]
3. The Clinical Impact of Capmatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification.
Choi W; Park SY; Lee Y; Lim KY; Park M; Lee GK; Han JY
Cancer Res Treat; 2021 Oct; 53(4):1024-1032. PubMed ID: 33540494
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of Perfluoro-tert-butyl Tyrosine, for Application in
Tressler CM; Zondlo NJ
Org Lett; 2016 Dec; 18(24):6240-6243. PubMed ID: 27978684
[TBL] [Abstract][Full Text] [Related]
5. Interstitial lung disease associated with capmatinib therapy in a patient with non-small cell lung cancer harboring a skipping mutation of MET exon 14.
Kanemura H; Takeda M; Shimizu S; Nakagawa K
Thorac Cancer; 2021 Feb; 12(4):549-552. PubMed ID: 33347701
[TBL] [Abstract][Full Text] [Related]
6. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Baltschukat S; Engstler BS; Huang A; Hao HX; Tam A; Wang HQ; Liang J; DiMare MT; Bhang HC; Wang Y; Furet P; Sellers WR; Hofmann F; Schoepfer J; Tiedt R
Clin Cancer Res; 2019 May; 25(10):3164-3175. PubMed ID: 30674502
[TBL] [Abstract][Full Text] [Related]
7. Perfluoro-tert-butyl Homoserine Is a Helix-Promoting, Highly Fluorinated, NMR-Sensitive Aliphatic Amino Acid: Detection of the Estrogen Receptor·Coactivator Protein-Protein Interaction by
Tressler CM; Zondlo NJ
Biochemistry; 2017 Feb; 56(8):1062-1074. PubMed ID: 28165218
[TBL] [Abstract][Full Text] [Related]
8. Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a
Cai B; Zhou ZY; Xue W; Hazra NC; Singh M; Mishra D; Brixner D; Oderda G; Biskupiak J
J Med Econ; 2021; 24(1):131-139. PubMed ID: 33397178
[TBL] [Abstract][Full Text] [Related]
9. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
10. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Mathieu LN; Larkins E; Akinboro O; Roy P; Amatya AK; Fiero MH; Mishra-Kalyani PS; Helms WS; Myers CE; Skinner AM; Aungst S; Jin R; Zhao H; Xia H; Zirkelbach JF; Bi Y; Li Y; Liu J; Grimstein M; Zhang X; Woods S; Reece K; Abukhdeir AM; Ghosh S; Philip R; Tang S; Goldberg KB; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Jan; 28(2):249-254. PubMed ID: 34344795
[TBL] [Abstract][Full Text] [Related]
11. Perfluoro-
Wu T; Li A; Chen K; Peng X; Zhang J; Jiang M; Chen S; Zheng X; Zhou X; Jiang ZX
Chem Commun (Camb); 2021 Aug; 57(63):7743-7757. PubMed ID: 34286714
[TBL] [Abstract][Full Text] [Related]
12. Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib.
Paik PK; Goyal RK; Cai B; Price MA; Davis KL; Ansquer VD; Caro N; Saliba TR
Future Oncol; 2023 Jan; 19(3):217-228. PubMed ID: 36749292
[No Abstract] [Full Text] [Related]
13. Capmatinib: First Approval.
Dhillon S
Drugs; 2020 Jul; 80(11):1125-1131. PubMed ID: 32557339
[TBL] [Abstract][Full Text] [Related]
14. Capmatinib for the treatment of non-small cell lung cancer.
Vansteenkiste JF; Van De Kerkhove C; Wauters E; Van Mol P
Expert Rev Anticancer Ther; 2019 Aug; 19(8):659-671. PubMed ID: 31368815
[No Abstract] [Full Text] [Related]
15. Perfluoro-
Tressler CM; Zondlo NJ
ACS Chem Biol; 2020 Apr; 15(4):1096-1103. PubMed ID: 32125821
[No Abstract] [Full Text] [Related]
16. Single low-dose INC280-loaded theranostic nanoparticles achieve multirooted delivery for MET-targeted primary and liver metastatic NSCLC.
Sun Y; Yang J; Li Y; Luo J; Sun J; Li D; Wang Y; Wang K; Yang L; Wu L; Sun X
Mol Cancer; 2022 Dec; 21(1):212. PubMed ID: 36457016
[TBL] [Abstract][Full Text] [Related]
17. Capmatinib for non-small cell lung cancer.
Alzofon N; Jimeno A
Drugs Today (Barc); 2021 Jan; 57(1):17-25. PubMed ID: 33594387
[TBL] [Abstract][Full Text] [Related]
18. Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics.
Guo MZ; Marrone KA; Spira A; Waterhouse DM; Scott SC
Onco Targets Ther; 2021; 14():5321-5331. PubMed ID: 34853516
[No Abstract] [Full Text] [Related]
19. MET inhibitor, capmatinib overcomes osimertinib resistance via suppression of MET/Akt/snail signaling in non-small cell lung cancer and decreased generation of cancer-associated fibroblasts.
Zhu K; Lv Z; Xiong J; Zheng H; Zhang S; Jin H; Yu L; Li Z; Zhang J; Li C; Liang P
Aging (Albany NY); 2021 Feb; 13(5):6890-6903. PubMed ID: 33621951
[TBL] [Abstract][Full Text] [Related]
20. Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study.
Grande E; Giovannini M; Marriere E; Pultar P; Quinlan M; Chen X; Rahmanzadeh G; Curigliano G; Cui X
Br J Clin Pharmacol; 2021 Jul; 87(7):2867-2878. PubMed ID: 33300203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]